Voorn Veronique M A, Marang-van de Mheen Perla J, van der Hout Anja, Hofstede Stefanie N, So-Osman Cynthia, van den Akker-van Marle M Elske, Kaptein Ad A, Stijnen Theo, Koopman-van Gemert Ankie W M M, Dahan Albert, Vliet Vlieland Thea P M M, Nelissen Rob G H H, van Bodegom-Vos Leti
Department of Medical Decision Making, Leiden University Medical Center, J10-S, P.O. Box 9600, 2300, RC, Leiden, The Netherlands.
Department of Orthopedic Surgery, Groene Hart Hospital, Bleulandweg 10, 2803, HH, Gouda, The Netherlands.
Implement Sci. 2017 May 30;12(1):72. doi: 10.1186/s13012-017-0601-0.
Perioperative autologous blood salvage and preoperative erythropoietin are not (cost) effective to reduce allogeneic transfusion in primary hip and knee arthroplasty, but are still used. This study aimed to evaluate the effectiveness of a theoretically informed multifaceted strategy to de-implement these low-value blood management techniques.
Twenty-one Dutch hospitals participated in this pragmatic cluster-randomized trial. At baseline, data were gathered for 924 patients from 10 intervention and 1040 patients from 11 control hospitals undergoing hip or knee arthroplasty. The intervention included a multifaceted de-implementation strategy which consisted of interactive education, feedback on blood management performance, and a comparison with benchmark hospitals, aimed at orthopedic surgeons and anesthesiologists. After the intervention, data were gathered for 997 patients from the intervention and 1096 patients from the control hospitals. The randomization outcome was revealed after the baseline measurement. Primary outcomes were use of blood salvage and erythropoietin. Secondary outcomes included postoperative hemoglobin, length of stay, allogeneic transfusions, and use of local infiltration analgesia (LIA) and tranexamic acid (TXA).
The use of blood salvage (OR 0.08, 95% CI 0.02 to 0.30) and erythropoietin (OR 0.30, 95% CI 0.09 to 0.97) reduced significantly over time, but did not differ between intervention and control hospitals (blood salvage OR 1.74 95% CI 0.27 to 11.39, erythropoietin OR 1.33, 95% CI 0.26 to 6.84). Postoperative hemoglobin levels were significantly higher (β 0.21, 95% CI 0.08 to 0.34) and length of stay shorter (β -0.36, 95% CI -0.64 to -0.09) in hospitals receiving the multifaceted strategy, compared with control hospitals and after adjustment for baseline. Transfusions did not differ between the intervention and control hospitals (OR 1.06, 95% CI 0.63 to 1.78). Both LIA (OR 0.0, 95% CI 0.0 to 0.0) and TXA (OR 0.3, 95% CI 0.2 to 0.5) were significantly associated with the reduction in blood salvage over time.
Blood salvage and erythropoietin use reduced over time, but not differently between intervention and control hospitals. The reduction in blood salvage was associated with increased use of local infiltration analgesia and tranexamic acid, suggesting that de-implementation is assisted by the substitution of techniques. The reduction in blood salvage and erythropoietin did not lead to a deterioration in patient-related secondary outcomes.
www.trialregister.nl, NTR4044.
围手术期自体血回输和术前促红细胞生成素在初次髋关节和膝关节置换术中减少异体输血方面并不(具有成本)效益,但仍在使用。本研究旨在评估一种理论上合理的多方面策略减少这些低价值血液管理技术使用的有效性。
21家荷兰医院参与了这项实用的整群随机试验。在基线时,收集了来自10家干预医院的924例患者和11家对照医院的1040例接受髋关节或膝关节置换术患者的数据。干预措施包括一项多方面的减少使用策略,该策略由互动教育、血液管理绩效反馈以及与标杆医院比较组成,针对骨科医生和麻醉医生。干预后,收集了干预医院的997例患者和对照医院的1096例患者的数据。基线测量后揭示随机分组结果。主要结局是自体血回输和促红细胞生成素的使用情况。次要结局包括术后血红蛋白水平、住院时间、异体输血以及局部浸润麻醉(LIA)和氨甲环酸(TXA)的使用情况。
随着时间推移,自体血回输(比值比0.08,95%置信区间0.02至0.30)和促红细胞生成素(比值比0.30,95%置信区间0.09至0.97)的使用显著减少,但干预医院和对照医院之间没有差异(自体血回输比值比1.74,95%置信区间0.27至11.39;促红细胞生成素比值比1.33,95%置信区间0.26至6.84)。与对照医院相比,接受多方面策略的医院术后血红蛋白水平显著更高(β值0.21,95%置信区间0.08至0.34),住院时间更短(β值 -0.36,95%置信区间 -0.64至 -0.09),且在对基线进行调整后也是如此。干预医院和对照医院之间的输血情况没有差异(比值比1.06,95%置信区间0.63至1.78)。随着时间推移,LIA(比值比0.0,95%置信区间0.0至0.0)和TXA(比值比0.3,95%置信区间0.2至0.5)均与自体血回输的减少显著相关。
随着时间推移,自体血回输和促红细胞生成素的使用减少,但干预医院和对照医院之间没有差异。自体血回输的减少与局部浸润麻醉和氨甲环酸使用的增加相关,这表明技术替代有助于减少使用。自体血回输和促红细胞生成素的减少并未导致与患者相关的次要结局恶化。